The BET inhibitor JQ1 targets fat metabolism and counteracts obesity.

Claudia Fornelli, Alessia Sofia Cento, Lorenzo Nevi, Raffaella Mastrocola, Gustavo Ferreira Alves, Giuseppina Caretti, Massimo Collino, Fabio Penna

Department of Clinical and Biological Sciences, University of Torino, Turin, Italy.Department of Clinical and Biological Sciences, University of Torino, Turin, Italy. · pubmed

Paper

Abstract

Obesity, one of the most frequent health problems in the adult population, is a condition characterized by excessive white adipose tissue accumulation and accompanied by the increased risk to develop other disorders such as type II diabetes, cardiovascular disorders, physical disability, frailty and sarcopenia. Total fat mass frequently increases during aging, often coexisting with sarcopenia, thus resulting in an emerging condition defined sarcopenic obesity (SO). Our previous data demonstrated the relevant role of the bromo and extra-terminal domain (BET) proteins inhibitor JQ1 in attenuating inflammation and fibrosis in sarcopenic mice. Moreover, we preliminarily observed that JQ1 administration markedly reduces white adipose tissue mass, suggesting a potential role of BET proteins on visceral fat deposition during aging.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper claims that the BET inhibitor JQ1 reduces white adipose tissue mass and may influence fat metabolism in the context of obesity. This research is relevant as it addresses the interplay between fat metabolism and aging-related conditions, specifically sarcopenic obesity, which is a significant concern in longevity research.

Author of this paper? Send a correction.